Literature DB >> 14719854

Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation.

Frank LoVecchio1, Jane Klemens, Elizabeth BoAnn Roundy, Annie Klemens.   

Abstract

OBJECTIVE: To describe the incidence and characteristics of serum sickness (SS) following administration of Wyeth Antivenin (Crotalidae) Polyvalent (ACP).
METHODS: A retrospective chart review was conducted involving presumed rattlesnake bite victims referred to our poison center. Serum sickness was defined as unexplained rash developing 3 to 21 days following the administration of ACP. Patients were monitored until complete resolution of all symptoms. Data collected included total number of ACP vials administered, associated signs and symptoms, duration of signs and symptoms, and medications used to treat SS.
RESULTS: Of the 181 cases included in our study, SS occurred in 102 (56%) patients. The frequency of SS in patients receiving fewer than 20, 20 to 29, 30 to 39, or 40 or more vials was 34%, 36%, 88%, and 100%, respectively. Duration of SS averaged 6.1 days (range, 1-21 days). Associated symptoms included subjective fever (49%), arthralgia (20%), and pruritus (40%). Reported medications used included prednisone (98%), antihistamines (92%), and histamine-2 blockers (3%).
CONCLUSIONS: Serum sickness following administration of Wyeth ACP is common, with a strong correlation between ACP dosage and SS frequency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14719854     DOI: 10.1580/1080-6032(2003)14[220:ssfaoa]2.0.co;2

Source DB:  PubMed          Journal:  Wilderness Environ Med        ISSN: 1080-6032            Impact factor:   1.518


  8 in total

Review 1.  Adverse reactions to snake antivenom, and their prevention and treatment.

Authors:  H Asita de Silva; Nicole M Ryan; H Janaka de Silva
Journal:  Br J Clin Pharmacol       Date:  2015-09-16       Impact factor: 4.335

2.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

3.  Early Experience with Crotalidae Immune F(ab')2 Antivenom to Treat Arizona Rattlesnake Envenomations.

Authors:  Anne-Michelle Ruha; Angela Padilla-Jones; Joshua Canning; Meghan B Spyres; Steven C Curry
Journal:  J Med Toxicol       Date:  2021-10-19

Review 4.  Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy.

Authors:  Manuela B Pucca; Felipe A Cerni; Isadora S Oliveira; Timothy P Jenkins; Lídia Argemí; Christoffer V Sørensen; Shirin Ahmadi; José E Barbosa; Andreas H Laustsen
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

Review 5.  Novel Treatment Strategy for Patients with Venom-Induced Consumptive Coagulopathy from a Pit Viper Bite.

Authors:  Eun Jung Park; Sangchun Choi; Hyuk-Hoon Kim; Yoon Seok Jung
Journal:  Toxins (Basel)       Date:  2020-05-05       Impact factor: 4.546

6.  Immunorecognition and Neutralization of Crotalus durissus cumanensis Venom by a Commercial Antivenom Produced in Colombia.

Authors:  Augusto Acosta-Peña; Vitelbina Núñez; Jaime Andres Pereañez; Paola Rey-Suárez
Journal:  Toxins (Basel)       Date:  2022-03-25       Impact factor: 5.075

Review 7.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

8.  A phase IV, prospective, observational study of the clinical safety of snake antivenoms.

Authors:  Denise Christie Souto Nogueira; Iara Pinheiro Calil; Roberta Márcia Marques Dos Santos; Adebal de Andrade Filho; Gláucia Cota
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2021-12-06       Impact factor: 1.846

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.